Emerald Clinics Ltd (ASX:EMD) has been granted a trading halt with news upcoming in regard to its real-world evidence data (RWE) platform.
The trading halt will remain in place until the beginning of regular ASX trading on Monday, June 22, or when an announcement is released to the market, whichever occurs earliest.
EMD securities last traded at 5.6 cents and in the last three months are up from 4 cents at the close on March 23.
National Clinical data platform
In early May, the company was promoted to program manager for the development of a national Clinical Data and Analytics Platform (CDAP) of COVID-19 patient cases.
As part of a partnership between several Australian state health bodies, the Federal Government and universities, the platform aims to collect clinical data from confirmed COVID-19 patients and a variety of sources in real-time.
The data will then be analysed to inform predictive models that can support point-of-care decision making by clinicians across likely disease progression as well as treatment options for each patient.
Additionally, the platform is expected to underpin a series of planned adaptive trials of COVID-19 treatment protocols while allowing for forecasting of likely demand on health services.